NSCLC

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

NSCLC
Sep 14, 2024, 17:39 | Blog
Amy C. Moore: Global biomarker testing survey focused on patients and caregivers diagnosed with NSCLC
Amy C. Moore shared post by Precision Oncology Connect on X: "For those attending ESMO24,…
Sep 14, 2024, 13:37 | Blog
Coral Olazagasti: Many laughs interviewing Charu Aggarwal and Rami Manochakian
Coral Olazagasti shared a post on X: ''So many laughs interviewing Charu Aggarwal and Rami…
Sep 14, 2024, 12:01 | Blog
Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!
Zhen Su, CEO at Marengo Therapeutics, posted the following on LinkedIn: “Phase III NSCLC Ivonescimab (Anti-VEGF/PD-1…
Sep 14, 2024, 10:51 | Blog
Tanja Obradovic: PIONeeR Project results will be presented at ESMO 2024 Presidential Symposium
Tanja Obradovic shared on LinkedIn: "Just announced that exciting results will be presented at ESMO…
Sep 14, 2024, 07:58 | Blog
Jessica Lin: Larotrectinib in TRK fusion+ NSCLC, presented at the WCLC24 today
Jessica Lin posted on X: "Pleased to share an updated efficacy, safety, and biomarker analysis…
Sep 13, 2024, 19:00 | Blog
Brian Shields discusses TROPION-Lung01 Clinical Trial and AI’s role in content curation
Brian Shields, Creator of KOL Pulse AI, posted the following on LinkedIn: “One of the…
Sep 13, 2024, 14:12 | Blog
Xiuning Le: BAY88 in pre-treated HER2-mut NSCLC
Xiuning Le shared  a post by Biagio Ricciuti, on X, adding: "BAY88 in pre-treated HER2-mut…
Sep 13, 2024, 12:06 | Blog
Aakash Desai: The biomarker landscape of ADCs and bispecific antibodies (BsAbs) in Lung cancer
Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn: "Excited to share…
Sep 13, 2024, 10:46 | Blog
Chris De Savi: Breaking News from WCLC24
Chris De Savi shared a post on LinkedIn: ''Ivonescimab Outshines Keytruda in 1st Line Lung…
Sep 13, 2024, 08:23 | Blog
Vivek Subbiah: HER2 mutant NSCLC now has an oral TKI option without ILD
Vivek Subbiah shared a post by Chul Kim, on X, adding: ''Wow! HER2 mutant non-small…
Sep 12, 2024, 19:27 | Blog
Felix Lichtenegger: Highly effective Steering Committee Meeting with leading US lung cancer specialists
Felix Lichtenegger, Vice President Clinical Development at CatalYm GmbH, reposted a post by CatalYm GmbH on LinkedIn,…
Sep 12, 2024, 19:20 | Blog
Herbert Loong: Join us at ESMO24 to discuss the emerging role of ADCs
Herbert Loong shared on LinkedIn: "Heading to Barcelona for ESMO24? Come join us on Saturday…
Sep 12, 2024, 15:39 | Blog
Rajat Thawani: Talking about biomarkers in lung cancer
Rajat Thawani, Assistant Professor, University of Chicago, shared a post by Physician's Weekly on X, adding:…
Sep 12, 2024, 10:06 | Blog
Rami Manochakian: The latest data in management of stage IV NSCLC at “Advancement in Oncology” event
Rami Manochakian shared a post on X: "The amazing experts Drs Narjust Florez & Jarushka Naidoo…
Sep 12, 2024, 09:48 | Insight
Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC
Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et…
Sep 12, 2024, 06:03 | Insight
Five articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey.…
Sep 11, 2024, 16:13 | Insight
RYBREVANT plus LAZCLUZE versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT plus LAZCLUZE regimen compared…
Sep 11, 2024, 13:54 | Blog
Noemi Reguart: Presidential Phase 3, Ivonescimab vs Pembrolizumab for PD-L1+ advanced NSCLC
Noemi Reguart shared a post on X: ''WCLC24 Presidential. Phase 3 Ivonescimab (AK112) versus Pembrolizumab…
Sep 11, 2024, 08:57 | Insight
TROPION-Lung01 Presents Further Data on Dato-DXd for NSCLC at WCLC - ASCO
American Society of Clinical Oncology (ASCO) shared a post on LinkedIn: "Lung Cancer Study (TROPION-Lung01)…
Sep 10, 2024, 13:45 | Societies
Rami Manochakian's key highlights from WCLC24
WCLC is a major international event focused on the latest advancements in lung cancer research,…
Sep 10, 2024, 13:18 | Societies
Keeping up with WCLC24 with Eric K. Singhi
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 9, 2024, 18:46 | Blog
Imran Sulaiman has been awarded a European Research Council Starting Grant
Jarushka Naidoo shared a post by Royal College of Surgeons in Ireland, on LinkedIn: "Super…
Sep 9, 2024, 15:30 | Societies
25 Posts Not To Miss from Day 2 of WCLC24
The International Association for the Study of Lung Cancer (IASLC) is a global, multidisciplinary organization committed…
Sep 9, 2024, 13:23 | Immune Oncology,Oncolibrary
Immunotherapy vs Chemotherapy: Success Rates, Side Effects, Costs Compared
When comparing immunotherapy vs chemotherapy, it's important to understand how these cancer treatments work differently.…
Sep 9, 2024, 11:35 | Societies
Inside WCLC24 - Recap by Estela Rodriguez
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 9, 2024, 09:55 | Societies
Insights from WCLC24 by Chul Kim
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 6, 2024, 07:04 | Blog
The first phase III trials of SBRT+/- Checkpoint inhibitors for stage 1 NSCLC
Corinne Faivre-Finn, Professor of Thoracic Radiation Oncology at the University of Manchester, shared a post…
Sep 4, 2024, 05:57 | Insight
Maria Lucia Reale: MET exon 14 skipping mutations in NSCLC
Maria Lucia Reale, Medical Oncologist at Vito Fazzi Hospital Company, shared on X: “Just out…
Sep 2, 2024, 09:38 | Insight
Antonio Passaro: EMA approves amivantamab in combination with chemo for treatment of advanced EGFR-mutated NSCLC after Osimertinib
Antonio Passaro, shared a post on X: "EMA approves amivantamab in combination with chemo for…
Sep 2, 2024, 08:32 | Insight
Drew Moghanaki: Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC
Drew Moghanaki shared a post on X about a paper by Gregory Videtic et al.…
Sep 2, 2024, 03:41 | Insight
FDA Grants Zongertinib Breakthrough Therapy Designation in HER2-Mutant NSCLC
The FDA has recently granted Zongertinib, a HER2-specific tyrosine kinase inhibitor (TKI), Breakthrough Therapy Designation…
Sep 1, 2024, 09:48 | Insight
Phase III Keynote-789 Trial of Platinum + Pemetrexed +/- Pembrolizumab in EGFR + NSCLC
Jarushka Naidoo shared a post on X: "Phase  III Keynote-789 Trial of Platinum + Pemetrexed +/-Pembro…
Aug 31, 2024, 20:07 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 31, 2024, 16:56 | Blog
Tanja Obradovic: GI INNOVATION announced collaboration with Merck
Tanja Obradovic shared a post on LinkedIn: "Tackling challenges of cancer patients treatment after they progressed…
Aug 30, 2024, 17:02 | Insight
Vivek Subbiah: A crucial leap forward in tissue - agnostic precision oncology
Amy C. Moore shared a post by Vivek Subbiah on X, adding: “Serving on the…
Aug 29, 2024, 17:01 | Insight
Elad Sharon: Quite promising for c-MET over-expressing NSCLC
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Giuseppe Banna, Consultant…
Aug 29, 2024, 16:15 | Drugs
Antonio Passaro: European Commission approves amivantamab
Antonio Passaro shared on LinkedIn: "I'm proud to announce that, yesterday August 27, the European…
Aug 28, 2024, 17:09 | Blog
Tanja Obradovic: Importance of vigilant toxicity monitoring
Tanja Obradovic shared a post on LinkedIn: "Importance of vigilant toxicity monitoring as well as early…
Aug 28, 2024, 10:52 | Insight
Some Lung Cancer Disparities Lessen in South Florida study led by Sylvester Comprehensive Cancer Center
When it comes to cancer disparities, community may count. A new study published August 21…
Aug 27, 2024, 22:13 | Insight
Stephen Liu: Final anaysis of WJOG9717L
Stephen Liu shared a post on X: “Final anaysis of WJOG9717L (phase II osimertinib +/-…
Aug 27, 2024, 22:06 | Insight
Giuseppe Banna: Promising results for Telisotuzumab Vedotin in advanced NSCLC
Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on…
Aug 26, 2024, 21:42 | Blog
Tanja Obradovic: Interesting update at ESMO 2024 on cancer-induced cachexia as PhII trial of ponsegromab
Tanja Obradovic posted on LinkedIn: “Interesting update will come at ESMO 2024 on possible option…
Aug 26, 2024, 21:24 | Blog
Tanja Obradovic: Can we expect new EGFR TKI to surpass osimertinib in primary tumor and intracranial progression of NSCLC
Tanja Obradovic posted on LinkedIn: “Can we expect new EGFR TKI that can significantly surpass…
Aug 26, 2024, 21:02 | Blog
Francesco Schettini: NGS of Actionable Genomic Alterations in Solid Tumors
Francesco Schettini, Medical Oncologist at the Breast Unit of the Hospital Clinic of Barcelona, posted…
Aug 26, 2024, 20:20 | Blog
Tanja Obradovic: Some points of interest from the Relativity-104 study
Tanja Obradovic shared on LinkedIn: "Opdualag, a cocktail of anti Lag-3 (relatlimab) and anti PD1…
Aug 26, 2024, 19:50 | Blog
Tanja Obradovic reflects on first KRAS G12C mutation inhibitor approval
Tanja Obradovic posted on LinkedIn: "First KRAS G12C mutation inhibitor just got approval in China.…
Aug 25, 2024, 17:20 | Dialogues
Beyond The Cancer Diagnosis: Dialogue with Sonia Amin Thomas, Hosted By Adrian Pogacian
For this latest episode of ‘Beyond the Cancer Diagnosis’, Adrian Pogacian debates the Psychological Dimension of NSCLC (Non-Small Cell…
Aug 25, 2024, 16:16 | Blog
World - first lung cancer vaccine trials launched across 7 countries
Lung cancer remains the top cause of cancer deaths worldwide, claiming around 1.8 million lives…
Aug 25, 2024, 12:38 | Blog
Fred R. Hirsch: What is the real impact of neo-adjuvant versus adjuvant therapy
Fred R. Hirsch, CEO of International Association for the Study of Lung Cancer, shared a…
Aug 25, 2024, 02:22 | Blog
First patient dosed in the UK with a new lung cancer vaccine - Oncogene Cancer Research
Oncogene Cancer Research shared a post on LinkedIn: "Big news out today in the UK:…
Aug 24, 2024, 20:21 | Insight
Hidehito Horinouchi summarizes some abstracts of WCLC24 part 3
Hidehito Horinouchi shared on X: Advancing Multimodal Therapies in Stage III NSCLC Chairs: Feng-Ming Spring Kong,…
Aug 24, 2024, 13:58 | Insight
Jennifer Marks: The new NSCLC FDA Oncology approvals
Jennifer Marks, Thoracic Oncologist at Georgetown Lombardi, shared a post on X, referencing an earlier…
Aug 24, 2024, 11:15 | Insight
Jill Feldman: Exciting news for the EGFR lung cancer community
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on…
Aug 23, 2024, 17:15 | Blog
Brian Shields: AI evaluates recent FDA decision
Brian Shields, Creator of KOL Pulse AI, shared on LinkedIn: "AI evaluates recent FDA decision:…
Aug 23, 2024, 14:20 | Blog
FDA Approves Johnson & Johnson's Chemotherapy-Free Regimen for EGFR-Mutated Lung Cancer
Kiran Patel, Vice President of Clinical Development in Solid Tumor Franchise at The Janssen Pharmaceutical…
Aug 22, 2024, 16:31 | Insight
Applications for ESMO Preceptorship on NSCLC and SCLC are open
ESMO – European Society for Medical Oncology shared on LinkedIn: “ESMO Preceptorship on NSCLC and…
Aug 22, 2024, 14:52 | Blog
New Lung Cancer Considered Episode with Narjust Florez and Julia Rotow
Florez Lab shared a post on X: "FDA approved lazertinib + amivantamab for first-line treatment…
Aug 22, 2024, 14:00 | Insight
Jarushka Naidoo: Phase II Lazertinib in EGFR+ NSCLC with CNS disease
Jarushka Naidoo shared a post on X: “Phase II Lazertinib in EGFR+ NSCLC with CNS disease,…
Aug 21, 2024, 17:08 | Insight
What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC
On August 19, 2024, the FDA approved a new combination therapy for advanced non-small cell…
Aug 20, 2024, 10:18 | Blog
Key points by Oncology Brothers on Durva+Chemo approval based off AEGEAN trial
H. Jack West, Vice President of Clinical Development at Summit Therapeutics, Inc, shared a post…
Aug 20, 2024, 10:11 | Blog
Jarushka Naidoo: Third neoadjuvant FDA approval in NSCLC
Jarushka Naidoo posted on X: "Third neoadjuvant FDA approval in NSCLC, now for perioperative durvalumab, based…
Aug 19, 2024, 11:40 | Insight
Brian Shields: Pfizer's CROWN study was a highlight of ASCO24
Brian Shields, Creator of KOL Pulse AI, shared on LinkedIn: “Pfizer's CROWN study was a…
Aug 18, 2024, 06:32 | Blog
Hidehito Horinouchi summarizes some abstracts of WCLC24 part 2
Hidehito Horinouchi shared on X: "Trailblazing Targets: New Insights Chairs: Drs. Jacob Sands and Lorenza Landi.…
Aug 18, 2024, 06:12 | Blog
Biagio Ricciuti: KEAPness signature outperforms deleterious KEAP1 mutations in predicting ICI efficacy in NSCLC
Biagio Ricciuti shared on X: "Sharing our latest effort out in Clinical Cancer Research! This multicenter…
Aug 17, 2024, 20:40 | Blog
Register for HTTR24 - IASLC
IASLC shared a post on X: "Register for HTTR24. Let's dive deep into the mechanisms, biomarkers…
Aug 17, 2024, 15:47 | Blog
Stephen V Liu: Nagla Abdel Karim joins DC Lung24 to discuss targeted therapy in NSCLC
Stephen V Liu shared on X: "Dr. Nagla Abdel Karim joins DC Lung24 to guide discussions…
Aug 17, 2024, 15:38 | Blog
Forging a Future For Precision Medicine - Lung MAP
Lung MAP shared a post on X: "The Lung-MAP precision medicine trial in non-small cell…
Aug 17, 2024, 08:15 | Blog
Mahadi Baig: U.S. FDA granted priority review of Johnson and Johnson Innovative Medicine's subcutaneous treatment for patients with EGFR-mutated NSCLC
Mahadi Baig, Global Medical Head, Amivantamab at Johnson and Johnson, shared a post on LinkedIn:…
Aug 16, 2024, 12:23 | Societies
Hidehito Horinouchi summarizes some abstracts of WCLC24
Hidehito Horinouchi shared on X: Antibody Drug Conjugates in SCLC by Charlie Rudin Ifinatamab Deruxtecan…
Aug 14, 2024, 13:49 | Insight
Amol Akhade: New and exciting data coming up at WLCC 24
Amol Akhade shared on X about recent papers: "What's new and exciting data coming up…
Aug 14, 2024, 03:35 | Insight
Hidehito Horinouchi: Presidential 2, WCLC24 abstracts titles
Hidehito Horinouchi, Oncologist at the Department of Thoracic Oncology at the National Cancer Center Hospital,…
Aug 14, 2024, 01:53 | Insight
5 papers about lung cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 13, 2024, 09:57 | Blog
Zosia Piotrowska about what's next for EGFR at DCLung24
Stephen V Liu posted on X: "Dr. Zosia Piotrowska from MGH Thoracic Oncology will discuss…
Aug 12, 2024, 06:51 | Blog
Remembering Susan Wojcicki, Honoring a Legacy of Leadership and Technological Innovation
In the ever-evolving landscape of Silicon Valley, few figures have left as indelible a mark…
Aug 11, 2024, 19:47 | Blog
Praveen Kumar Marimuthu: Phase 2 trial Carboplatin, Pemetrexed, Cetuximab for advanced NSCLC
Praveen Kumar Marimuthu, Final year Medical Oncology Trainee at CMC Vellore, shared on X: "OPEN FOR…
Aug 11, 2024, 13:07 | Insight
Targeting serine/glycine metabolism with sertraline can enhance radiotherapy responses in NSCLC - ESTRO
European Society for Radiotherapy and Oncology (ESTRO) shared on LinkedIn: "Pre-clinical findings presented at ESTRO24…
Aug 10, 2024, 13:45 | Insight
Katsuaki Maehara: EGFR mutated NSCLC
Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X: “EGFR mutated NSCLC.…
Aug 9, 2024, 01:47 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 8, 2024, 20:53 | Insight
Manuel Dómine: Management and treatment of adverse events using lorlatinib in ALK-positive NSCLC
Manuel Dómine, Associate Head Oncology at Jiménez Díaz Foundation, shared a post on X about…
Aug 8, 2024, 02:34 | Blog
Dr. Isabel Preeshagul will discuss perioperative targeted therapy for lung cancer at DCLung24
Stephen V Liu shared on X: “Dr. Isabel Preeshagul will discuss perioperative targeted therapy for…
Aug 5, 2024, 10:25 | Insight
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few…
Aug 5, 2024, 08:03 | Blog
Alessio Cortellini: Project on family history in patients with NSCLC is now up and running
Alessio Cortellini, Assistant Professor at Campus Bio-Medico University of Rome, shared a post on X, about…
Aug 5, 2024, 04:49 | Drugs
Maria Babak: Key highlight from The Babak Lab on FDA Approval for Adagrasib
Maria Babak shared a post by The Babak Lab on LinkedIn: "This FDA approval represents…
Aug 4, 2024, 06:02 | Blog
Rahul Gosain: With Patrick Forde we discuss the SoC for early and locally advanced NSCLC
Rahul Gosain shared on LinkedIn: "Lung Series: with Patrick Forde we discuss the SoC for…
Aug 3, 2024, 22:57 | Blog
Ru Xin Wong: Co-chaired SSO radiation oncology track with Bala Vellayappan
Wen Shen Looi, Head and Consultant Radiation Oncologist at Proton Therapy SG, Singapore Institute of…
Aug 3, 2024, 02:04 | Blog
Rasha Aboelhassan: Maha passed away wondering if there are any screening opportunities for passive smoking
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on Linkedin: "I…
Aug 1, 2024, 08:13 | Blog
Jennifer Marks: 2024 NSCLC management algorithm for boards
Jennifer Marks, Hematologist and Oncologist at MedStar Georgetown University Hospital, shared on X: "Feels way more…
Jul 31, 2024, 14:18 | Blog
Formycon announced start of clinical phase III trial for Keytruda biosimilar candidate FYB206
Formycon AG announced that the first patient has been enrolled in the Phase III clinical…
Jul 31, 2024, 09:17 | Blog
New Lung Cancer Considered episode, the use of ICIs in the treatment of molecular driven NSCLC
IASLC shared on X: "In this Lung Cancer Considered episode, Narjust Florez and 2 esteemed…
Jul 31, 2024, 06:23 | Societies
3 days left to submit your abstracts for Hot Topic in Basic and Translational Science 2024 - IASLC
IASLC (International Association for the Study of Lung Cancer) shared a post on X: "Only…
Jul 30, 2024, 16:53 | Insight
Luis Raez: Clinical and Economic Outcomes for Advanced NSCLC Patients in Trials After Liquid Biopsy
Luis Raez shared a post on LinkedIn about a recent paper titled "Real-world clinical and…
Jul 30, 2024, 13:41 | Insight
Brendon Stiles: Neoadjuvant chemo-ICI in marginally resectable patients
Brendon Stiles, Professor and Chief of Thoracic Surgery and Surgical Oncology at Montefiore Health System,…
Jul 30, 2024, 07:19 | Blog
No one is Missed's mission to ensure access to biomarker testing and treatment for NSCLC patients - LUNGevity Foundation
LUNGevity Foundation shared on X: "No One Missed is working to combat barriers to receiving…
Jul 30, 2024, 06:39 | Insight
Ph II KUPENG trial of Vebreltinib in Advanced MetExon14 and NSCLC
Jarushka Naidoo shared a post on X about a recent paper by Jin-Ji Yang et…
Jul 30, 2024, 02:53 | Blog
Giannis Mountzios: Huge pleasure to discuss advances in Precision oncology in NSCLC with Elsa Anagnostou and Ferdinandos Skoulidis
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jul 30, 2024, 01:45 | Insight
TKIs with vs without upfront SRS for EGFR+ and ALK+ NSCLC and brain metastasis
Biagio Ricciuti shared on X about a recent paper by Luke Pike et al. titled…
Jul 29, 2024, 21:28 | Insight
RWO with chemotherapy for patients who progress after PACIFIC regimen
Stephen Liu shared a post on X about a recent paper by Hayato Kawachi et al.…
Jul 29, 2024, 09:20 | Insight
PD-L1 and durvalumab after chemoradiation for stage III NSCLC in Netherlands Cancer Registry
Stephen Liu shared on X about a recent paper by Damhuis Ram et al. titled…
Jul 29, 2024, 07:52 | Insight
Amy Moore: Narjust Florez will lead a breakout session about Lung Cancer in Young Adults at ILCSC 24
Amy Moore, Vice-President of Global Engagement and Research Partnerships at LUNGevity Foundation, shared Lung Cancer…
Jul 29, 2024, 06:48 | Drugs
ODAC reviewed IMFINZI for treatment of resectable NSCLC based on AEGEAN Phase III trial results
Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at AstraZeneca, shared a post on…
All: 355 Posts: 1 - 100
Special Coverage